Tempest Therapeutics (TPST) Competitors $10.13 +0.12 (+1.20%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$10.21 +0.08 (+0.78%) As of 09/19/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TPST vs. NLTX, ENTA, BIOA, IVVD, TVGN, KYTX, CABA, CRBU, BTMD, and MISTShould you be buying Tempest Therapeutics stock or one of its competitors? The main competitors of Tempest Therapeutics include Neoleukin Therapeutics (NLTX), Enanta Pharmaceuticals (ENTA), BioAge Labs (BIOA), Invivyd (IVVD), Tevogen Bio (TVGN), Kyverna Therapeutics (KYTX), Cabaletta Bio (CABA), Caribou Biosciences (CRBU), biote (BTMD), and Milestone Pharmaceuticals (MIST). These companies are all part of the "pharmaceutical products" industry. Tempest Therapeutics vs. Its Competitors Neoleukin Therapeutics Enanta Pharmaceuticals BioAge Labs Invivyd Tevogen Bio Kyverna Therapeutics Cabaletta Bio Caribou Biosciences biote Milestone Pharmaceuticals Tempest Therapeutics (NASDAQ:TPST) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings. Is TPST or NLTX more profitable? Neoleukin Therapeutics' return on equity of -37.22% beat Tempest Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Tempest TherapeuticsN/A -334.76% -130.63% Neoleukin Therapeutics N/A -37.22%-30.91% Do analysts prefer TPST or NLTX? Tempest Therapeutics presently has a consensus price target of $30.00, suggesting a potential upside of 196.15%. Given Tempest Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tempest Therapeutics is more favorable than Neoleukin Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tempest Therapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility and risk, TPST or NLTX? Tempest Therapeutics has a beta of -1.93, suggesting that its stock price is 293% less volatile than the S&P 500. Comparatively, Neoleukin Therapeutics has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500. Which has better valuation and earnings, TPST or NLTX? Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTempest TherapeuticsN/AN/A-$41.84M-$14.59-0.69Neoleukin TherapeuticsN/AN/A-$57.56M-$3.11-6.01 Does the media prefer TPST or NLTX? In the previous week, Tempest Therapeutics' average media sentiment score of 0.00 equaled Neoleukin Therapeutics'average media sentiment score. Company Overall Sentiment Tempest Therapeutics Neutral Neoleukin Therapeutics Neutral Do institutionals & insiders hold more shares of TPST or NLTX? 22.5% of Tempest Therapeutics shares are owned by institutional investors. Comparatively, 52.4% of Neoleukin Therapeutics shares are owned by institutional investors. 4.7% of Tempest Therapeutics shares are owned by insiders. Comparatively, 1.6% of Neoleukin Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryTempest Therapeutics beats Neoleukin Therapeutics on 6 of the 11 factors compared between the two stocks. Get Tempest Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TPST and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TPST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TPST vs. The Competition Export to ExcelMetricTempest TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$44.45M$2.58B$5.79B$10.40BDividend YieldN/A55.37%5.63%4.60%P/E Ratio-0.6922.7276.4826.75Price / SalesN/A689.96531.72124.23Price / CashN/A175.2537.9261.55Price / Book1.795.3513.726.40Net Income-$41.84M$32.95M$3.29B$271.62M7 Day Performance-1.27%0.90%2.65%3.46%1 Month Performance7.54%5.76%6.01%9.87%1 Year Performance-42.28%-3.43%80.02%28.45% Tempest Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TPSTTempest Therapeutics1.6995 of 5 stars$10.13+1.2%$30.00+196.2%-44.7%$44.45MN/A-0.6920NLTXNeoleukin TherapeuticsN/A$19.00-5.4%N/A-55.1%$178.56MN/A-6.1190High Trading VolumeENTAEnanta Pharmaceuticals4.0223 of 5 stars$7.46-9.9%$20.20+170.8%-32.4%$177.01M$67.64M-1.73160High Trading VolumeBIOABioAge Labs0.035 of 5 stars$4.80flatN/AN/A$172.08MN/A0.00N/AHigh Trading VolumeIVVDInvivyd3.4472 of 5 stars$1.28-10.5%$3.18+148.7%+0.0%$171.80M$25.38M-1.39100TVGNTevogen Bio2.0407 of 5 stars$0.84-2.7%$10.00+1,087.5%+72.4%$170.29MN/A-4.433KYTXKyverna Therapeutics2.8344 of 5 stars$3.91-0.3%$16.60+324.6%-16.2%$169.52M$7.03M-1.0696Gap UpCABACabaletta Bio3.0665 of 5 stars$1.91+3.8%$14.50+659.2%-53.4%$168.30MN/A-0.7050News CoveragePositive NewsCRBUCaribou Biosciences2.8597 of 5 stars$1.83+1.7%$6.67+264.3%-18.4%$167.62M$9.99M-1.03100News CoveragePositive NewsBTMDbiote2.8798 of 5 stars$3.45+2.4%$6.00+73.9%-48.3%$166.61M$197.19M3.83194Positive NewsMISTMilestone Pharmaceuticals2.4235 of 5 stars$1.97+0.5%$4.50+128.4%+23.9%$166.59M$1M-2.3530 Related Companies and Tools Related Companies NLTX Alternatives ENTA Alternatives BIOA Alternatives IVVD Alternatives TVGN Alternatives KYTX Alternatives CABA Alternatives CRBU Alternatives BTMD Alternatives MIST Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TPST) was last updated on 9/20/2025 by MarketBeat.com Staff From Our PartnersPrepare for the “Mar-a-Lago Accord” Money ShockWhy Are Wall Street Insiders Moving Their Money to This ONE Asset? Something far more consequential for you...Stansberry Research | SponsoredWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredTurn $1K into $50K with This DeFi GemBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tempest Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tempest Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TPST Stock Alerts